biote (BTMD) Competitors $2.89 -0.05 (-1.70%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$2.89 0.00 (0.00%) As of 10/24/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BTMD vs. ARCT, KALV, ESPR, INBX, PRTA, CTMX, CRVS, LXEO, ORGO, and CYRXShould you be buying biote stock or one of its competitors? The main competitors of biote include Arcturus Therapeutics (ARCT), KalVista Pharmaceuticals (KALV), Esperion Therapeutics (ESPR), Inhibrx Biosciences (INBX), Prothena (PRTA), CytomX Therapeutics (CTMX), Corvus Pharmaceuticals (CRVS), Lexeo Therapeutics (LXEO), Organogenesis (ORGO), and CryoPort (CYRX). These companies are all part of the "pharmaceutical products" industry. biote vs. Its Competitors Arcturus Therapeutics KalVista Pharmaceuticals Esperion Therapeutics Inhibrx Biosciences Prothena CytomX Therapeutics Corvus Pharmaceuticals Lexeo Therapeutics Organogenesis CryoPort biote (NASDAQ:BTMD) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations. Do insiders & institutionals have more ownership in BTMD or ARCT? 21.7% of biote shares are held by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are held by institutional investors. 24.0% of biote shares are held by company insiders. Comparatively, 16.6% of Arcturus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media favor BTMD or ARCT? In the previous week, Arcturus Therapeutics had 38 more articles in the media than biote. MarketBeat recorded 45 mentions for Arcturus Therapeutics and 7 mentions for biote. biote's average media sentiment score of 0.79 beat Arcturus Therapeutics' score of 0.06 indicating that biote is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment biote 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcturus Therapeutics 3 Very Positive mention(s) 8 Positive mention(s) 12 Neutral mention(s) 7 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate BTMD or ARCT? biote presently has a consensus target price of $6.00, suggesting a potential upside of 107.61%. Arcturus Therapeutics has a consensus target price of $31.71, suggesting a potential upside of 182.66%. Given Arcturus Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Arcturus Therapeutics is more favorable than biote.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score biote 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33Arcturus Therapeutics 1 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.64 Which has higher valuation and earnings, BTMD or ARCT? biote has higher revenue and earnings than Arcturus Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratiobiote$197.19M0.72$3.16M$0.903.21Arcturus Therapeutics$152.31M2.00-$80.94M-$2.23-5.03 Is BTMD or ARCT more profitable? biote has a net margin of 15.73% compared to Arcturus Therapeutics' net margin of -49.26%. biote's return on equity of -21.00% beat Arcturus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets biote15.73% -21.00% 18.26% Arcturus Therapeutics -49.26%-24.87%-17.75% Which has more risk and volatility, BTMD or ARCT? biote has a beta of 1.16, suggesting that its stock price is 16% more volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 2.39, suggesting that its stock price is 139% more volatile than the S&P 500. Summarybiote beats Arcturus Therapeutics on 9 of the 17 factors compared between the two stocks. Get biote News Delivered to You Automatically Sign up to receive the latest news and ratings for BTMD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BTMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BTMD vs. The Competition Export to ExcelMetricbioteMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$142.88M$11.08B$6.21B$10.81BDividend YieldN/A1.88%5.72%4.80%P/E Ratio3.2121.4531.6030.98Price / Sales0.7231.07595.06133.64Price / Cash3.7725.0837.2561.86Price / Book-1.043.5012.056.61Net Income$3.16M$210.63M$3.34B$277.10M7 Day Performance1.76%0.74%1.94%2.57%1 Month Performance-3.34%2.73%6.88%3.20%1 Year Performance-43.66%-7.76%56.06%33.22% biote Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BTMDbiote2.6564 of 5 stars$2.89-1.7%$6.00+107.6%-43.7%$142.88M$197.19M3.21194News CoverageAnalyst UpgradeARCTArcturus Therapeutics3.4416 of 5 stars$21.51+4.1%$50.57+135.1%-40.8%$561.01M$152.31M-9.65180Trending NewsAnalyst DowngradeAnalyst RevisionKALVKalVista Pharmaceuticals3.6166 of 5 stars$11.54+4.0%$26.43+129.0%-4.7%$560.81MN/A-2.93100Analyst ForecastESPREsperion Therapeutics3.7164 of 5 stars$2.82+2.5%$7.00+148.2%+29.0%$554.46M$332.31M-5.76200Analyst ForecastINBXInhibrx Biosciences2.0358 of 5 stars$38.22+2.6%N/A+272.7%$539.58M$200K-3.61166Trending NewsAnalyst ForecastGap UpPRTAProthena2.5264 of 5 stars$10.37+4.5%$20.50+97.7%-35.8%$533.99M$135.16M-1.84130Positive NewsCTMXCytomX Therapeutics4.3621 of 5 stars$3.74+16.9%$5.42+44.8%+216.5%$527.72M$138.10M6.68170Analyst ForecastCRVSCorvus Pharmaceuticals2.0982 of 5 stars$7.47+6.1%$13.75+84.1%-11.6%$524.58MN/A-7.4030Positive NewsAnalyst ForecastLXEOLexeo Therapeutics2.8242 of 5 stars$9.22-3.8%$18.86+104.5%-2.8%$517.33M$650K-2.8358Trending NewsAnalyst ForecastAnalyst RevisionORGOOrganogenesis4.0034 of 5 stars$4.08+1.0%$7.33+79.7%+52.1%$512.51M$482.04M-29.14950Analyst ForecastCYRXCryoPort2.895 of 5 stars$10.54+4.2%$12.56+19.1%+56.2%$506.68M$228.38M7.921,186Analyst ForecastGap Up Related Companies and Tools Related Companies Arcturus Therapeutics Alternatives KalVista Pharmaceuticals Alternatives Esperion Therapeutics Alternatives Inhibrx Biosciences Alternatives Prothena Alternatives CytomX Therapeutics Alternatives Corvus Pharmaceuticals Alternatives Lexeo Therapeutics Alternatives Organogenesis Alternatives CryoPort Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BTMD) was last updated on 10/26/2025 by MarketBeat.com Staff From Our PartnersU.S. Government Sparking Crypto RallyMissed Bitcoin when it was $100? You’re not alone. Crypto runs in cycles—and the next one is already underw...Crypto 101 Media | SponsoredIt’s Time to Buy “the NVIDIA of Quantum Computing”Yahoo Finance wrote that investing in quantum computing could... "Lead to life-changing returns... and make...Brownstone Research | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredBuy the dip? Here’s my #1 gold stock“The most obvious opportunity in gold stocks I’ve seen in my career” While everyone is distracted by gold’s...Golden Portfolio | SponsoredThe strategy that wins no matter where the market goesJoel and Adam have built a crypto trading system with a 93% win rate — even through volatile, sideways markets...Crypto Swap Profits | SponsoredOptions Pro Reveals His #1 Retirement Income TradeIf you want a way to generate consistent market income without chasing volatile AI stocks or complex crypto tr...Base Camp Trading | SponsoredElon Musk is on the lineElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding biote Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share biote With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
